Clinical trial
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
NCT00940225 · Exelixis, Industry · Completed
Key facts
| NCT number | NCT00940225 |
|---|---|
| Title | Study of Cabozantinib (XL184) in Adults With Advanced Malignancies |
| Official title | A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors |
| Lead sponsor | Exelixis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Solid Tumors, Cancer |
| Intervention type | Drug |
| Interventions | Cabozantinib, Placebo |
| Enrollment | 730 |
| Start date | Sep 1, 2009 |
| Primary completion | May 1, 2013 |
| Completion | Jun 1, 2014 |
| First posted | Jul 15, 2009 |
| Last update posted | Apr 25, 2024 |
| Countries | Belgium, Israel, Taiwan, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: